These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 7758262)

  • 1. The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia.
    Stewart MW; Dyer RG; Alberti KG; Laker MF
    Diabet Med; 1995 Mar; 12(3):250-7. PubMed ID: 7758262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive lipid-lowering strategy in patients with diabetes mellitus.
    Kanters SD; Algra A; de Bruint TW; Erkelens DW; Banga JD
    Diabet Med; 1999 Jun; 16(6):500-8. PubMed ID: 10391399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia.
    Hutchesson AC; Moran A; Jones AF
    J Clin Pharm Ther; 1994 Dec; 19(6):387-9. PubMed ID: 7876371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
    Jeck T; Riesen WF; Keller U
    Diabet Med; 1997 Jul; 14(7):564-70. PubMed ID: 9223394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
    Rustemeijer C; Schouten JA; Voerman HJ; Hensgens HE; Donker AJ; Heine RJ
    Diabetes Metab Res Rev; 2000; 16(2):82-7. PubMed ID: 10751747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins.
    Nakandakare E; Garcia RC; Rocha JC; Sperotto G; Oliveira HC; Quintão EC
    Atherosclerosis; 1990 Dec; 85(2-3):211-7. PubMed ID: 2102085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of acipimox in patients with type 2 diabetes and persistent hyperlipidaemia.
    Dean JD; McCarthy S; Betteridge DJ; Whately-Smith C; Powell J; Owens DR
    Diabet Med; 1992; 9(7):611-5. PubMed ID: 1511566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
    Davoren PM; Kelly W; Gries FA; Hubinger A; Whately-Smith C; Alberti KG
    Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia.
    Kehely A; MacMahon M; Barbir M; Wray R; Hunt BJ; Prescott RJ; Thompson GR
    QJM; 1995 Jun; 88(6):421-7. PubMed ID: 7648234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis.
    Kawano M; Kuroda Y; Terao M; Yaginuma T; Kawakami M; Kanazawa Y
    Clin Chim Acta; 2002 Apr; 318(1-2):91-5. PubMed ID: 11880117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of simvastatin and bezafibrate on bile composition and gall-bladder emptying in female non-insulin-dependent diabetics.
    Wilson IR; Hurrell MA; Pattinson NR; Chapman BA
    J Gastroenterol Hepatol; 1994; 9(5):447-51. PubMed ID: 7827294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus. NIDDM Study Group.
    Sweany AE; Shapiro DR; Tate AC; Goldberg RB; Stein EA
    Clin Ther; 1995; 17(2):186-203. PubMed ID: 7614520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus.
    Fulcher GR; Catalano C; Walker M; Farrer M; Thow J; Whately-Smith CR; Alberti KG
    Diabet Med; 1992 Dec; 9(10):908-14. PubMed ID: 1478035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study.
    Tikkanen MJ; Laakso M; Ilmonen M; Helve E; Kaarsalo E; Kilkki E; Saltevo J
    Diabetes Care; 1998 Apr; 21(4):477-81. PubMed ID: 9571327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures.
    Farrer M; Winocour PH; Evans K; Neil HA; Laker MF; Kesteven P; Alberti KG
    Diabetes Res Clin Pract; 1994 Mar; 23(2):111-9. PubMed ID: 8070302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
    Diabetes Atorvastin Lipid Intervention (DALI) Study Group
    Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.
    Schulzeck P; Bojanovski M; Jochim A; Canzler H; Bojanovski D
    Lancet; 1988 Mar; 1(8586):611-3. PubMed ID: 2894548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Bruckert E; De Gennes JL; Malbecq W; Baigts F
    Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
    Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
    Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case for lipid-lowering?
    Durrington P
    Diabet Med; 2000 Sep; 17 Suppl 2():4-5. PubMed ID: 11048824
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.